Recombinant Human B-Cell Lymphoma/Leukemia 10 (BCL10) Protein (His-SUMO)

Name: Recombinant Human B-Cell Lymphoma/Leukemia 10 (BCL10) Protein (His-SUMO)
Brand: Beta LifeScience
SKU: BLC-04359P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human B-Cell Lymphoma/Leukemia 10 (BCL10) Protein (His-SUMO) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	O95999
Target Symbol	BCL10
Synonyms	AI132454; B cell CLL/lymphoma 10 ; B cell lymphoma/leukemia10; B-cell CLL/lymphoma 10; B-cell leukemia/lymphoma 10; B-cell lymphoma/leukemia 10; Bcl 10; Bcl-10; Bcl10; BCL10_HUMAN; c E10; c-E10; C81403; CARD containing apoptotic signaling protein; CARD containing molecule enhancing NF kappa B; CARD containing molecule enhancing NF kB; CARD containing molecule enhancing NF-kB; CARD containing molecule enhancing NFkB ; CARD containing proapoptotic protein; CARD like apoptotic protein ; CARD-containing apoptotic signaling protein; CARD-containing molecule enhancing NF-kappa-B; CARD-containing proapoptotic protein; CARD-like apoptotic protein; CARMEN; Caspase recruiting domain containing protein ; caspase-recruiting domain-containing protein; cCARMEN; cE 10; cE10 ; CED 3/ICH 1 prodomain homologous E10 like regulator; CED-3/ICH-1 prodomain homologous E10-like regulator; CED3/ICH1 prodomain homologous E10 like regulator; Cellular E10; Cellular homolog of vCARMEN; Cellular-E10; CIPER; CLAP; hCLAP; Mammalian CARD containing adapter molecule E10; Mammalian CARD-containing adapter molecule E10; mE 10; mE10; R-RCD1
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His-SUMO
Target Protein Sequence	MEPTAPSLTEEDLTEVKKDALENLRVYLCEKIIAERHFDHLRAKKILSREDTEEISCRTSSRKRAGKLLDYLQENPKGLDTLVESIRREKTQNFLIQKITDEVLKLRNIKLEHLKGLKCSSCEPFPDGATNNLSRSNSDESNFSEKLRASTVMYHPEGESSTTPFFSTNSSLNLPVLEVGRTENTIFSSTTLPRPGDPGAPPLPPDLQLEEEGTCANSSEMFLPLRSRTVSRQ
Expression Range	1-233aa
Protein Length	Full Length
Mol. Weight	42.3kDa
Research Area	Apoptosis
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Plays a key role in both adaptive and innate immune signaling by bridging CARD domain-containing proteins to immune activation. Acts by channeling adaptive and innate immune signaling downstream of CARD domain-containing proteins CARD9, CARD11 and CARD14 to activate NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines. Recruited by activated CARD domain-containing proteins: homooligomerized CARD domain-containing proteins form a nucleating helical template that recruits BCL10 via CARD-CARD interaction, thereby promoting polymerization of BCL10, subsequent recruitment of MALT1 and formation of a CBM complex. This leads to activation of NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines. Activated by CARD9 downstream of C-type lectin receptors; CARD9-mediated signals are essential for antifungal immunity. Activated by CARD11 downstream of T-cell receptor (TCR) and B-cell receptor (BCR). Promotes apoptosis, pro-caspase-9 maturation and activation of NF-kappa-B via NIK and IKK.
Subcellular Location	Cytoplasm, perinuclear region. Membrane raft.
Database References	HGNC: 989 OMIM: 137245 KEGG: hsa:8915 STRING: 9606.ENSP00000271015 UniGene: PMID: 29358699 BCL10 forms CARMA1-BCL10-MALT1-TRAF6 signalosome and BCL10 polymerizes in a unidirectional manner. PMID: 29382759 The results suggest that the involvement of BCL10 in DNA damage-induced NF-kappaB is through the recruitment of TRAF6. PMID: 28717989 results define molecular determinants that control the production of Lin(Ub)n-Bcl10, an important signaling intermediate in TCR and oncogenic CARD11 signaling. PMID: 27777308 Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-kappaB activation PMID: 27071417 BCL10 promoted DNA double-strand breaks repair, enhancing cell survival after DNA damage. PMID: 26771713 Data show that caspase recruitment domain-containing protein 11/B-cell CLL/lymphoma 10/mucosa-associated lymphoid tissue lymphoma translocation gene 1 signaling drives lymphoproliferation through NF-kappa B and c-Jun N-terminal kinase activation. PMID: 26668357 BCL10 is not essential for actin polymerization after fibroblast FcgammaR stimulation. PMID: 26774590 characterization of zebrafish (Danio rerio) Bcl10 PMID: 25849213 we identified BCL10 as a bona fide target of BCR-induced linear ubiquitylation and demonstrated an important role of the linear ubiquitin ligase HOIP in BCR-induced phosphorylation PMID: 26038114 The results of this study indicate that inherited BCL10 deficiency should be considered in patients with combined immunodeficiency with B cell, T cell, and fibroblast defects. PMID: 25365219 B-cell lymphoma/leukemia 10 promotes oral cancer progression through STAT1/ATF4/S100P signaling pathway. PMID: 24681956 BCL10 induces cleavage of MALT1 at R149 in 293T cells. PMID: 25105596 Overexpression of CARMA-BCL10-MALT in T-ALL may contribute to the constitutive cleavage and inactivation of A20, which enhances NF-kappaB signaling and may be related to T-ALL pathogenesis. PMID: 25384343 BCL10 delivers UBC13 to RNF8/RNF168 to regulate ubiquitination-mediated double-strand break signaling and repair. PMID: 24732096 elevated in cholesteatoma PMID: 24702227 A novel susceptibility locus on 1p22 was discovered, which implicates BCL10 as a new susceptibility gene for leprosy. PMID: 23784377 Combining crystallography, nuclear magnetic resonance, and electron microscopy, we reveal the structure of the Bcl10 CARD filament and the mode of interaction between CARMA1 and Bcl10 PMID: 24074955 BCL10 expression is a useful marker for acinar cell differentiation, particularly in the diagnosis of endoscopic ultrasound-guided fine-needle aspiration specimens of Acinar cell carcinomas of the pancreas PMID: 23530562 Bcl10 links saturated fat overnutrition with hepatocellular NF-kB activation and insulin resistance. PMID: 22708078 BCL10 was commonly down-regulated in peripheral T cell lymphomas, suggest the T-cell receptor signaling cascade for future characterization. PMID: 22818167 identify Bcl10 as an early coordinator of NF-kappaB-mediated immune response with endosomal trafficking and signaling to F-actin remodeling PMID: 23153494 Results indicate that NF-kappaB binding to the BCL10 promoter can lead to prolonged activation of the carrageenan-induced inflammatory cascade by a transcriptional mechanism involving an NF-kappaB-BCL10 loop. PMID: 22579587 A proapoptotic role for protein kinase C zeta in the binding and phosphorylating Bcl10 at the nuclear envelope. PMID: 22812606 BCL10 plays an important role in controlling the growth of cervical cancer cells through NF-kappaB dependent cyclin D1 regulation. PMID: 22564715 FOXO3a promotes cell survival via BCL10/NF-kappaB in serum starvation PMID: 22474286 identify MIB2 as a novel component of the activated BCL10 signaling complex and a missing link in the BCL10-dependent NF-kappaB signaling pathway. PMID: 21896478 findings indicate that BCL10 phosphorylations act upstream of phosphorylations of NIK, TAK1, and IkappaBalpha and differentially affect the canonical and noncanonical pathways of NF-kappaB activation PMID: 21700900 Findings demonstrate that CaN functions as a critical signaling molecule during Th cell activation, regulating Bcl-10 phosphorylation and NF-kappaB activation. PMID: 21674474 study shows CaMKII is recruited to the immunological synapse where it interacts with and phosphorylates Bcl10; propose a mechanism whereby Ca(2+) signals can be integrated at the immunological synapse through CaMKII-dependent phosphorylation of Bcl10 PMID: 21513986 Data show that CARMA3 and Bcl10 contributed to several characteristics of EGFR-associated malignancy, including proliferation, survival, migration, and invasion. PMID: 21406399 Lipopolysaccharide induces activation of both canonical and non-canonical pathways of NF-kappaB and the non-canonical pathway requires phosphorylations of BCL10 (serine 138) and NIK. PMID: 20466000 A novel mutation of Bc1-10 gene in ocular adnexal MALT lymphoma was detected in Chinese patients. PMID: 18307945 BCL10 nuclear expression is common in ocular adnexal mucosa-associated lymphoid tissue lymphomas. PMID: 19035248 activation of NF-kappaB by CXCR4 occurs through Carma3/Bcl10/Malt1 (CBM) complex in OSCC. loss of components of CBM complex in HNSCC can inhibit SDF-1 alpha induced phosphorylation and degradation of IkappaBalpha. PMID: 20695076 Interaction of calmodulin with Bcl10 modulates NF-kappaB activation. PMID: 20439115 A specific single nucleotide polymorphism in the BCL10 gene may be responsible for the tumorigenesis of intracranial germinomas in Japanese individuals. PMID: 19690445 Results suggest that the NFkappaB regulator BCL10 is an IL-2-independent STAT5 target gene. PMID: 19709433 These findings indicate an upstream signaling role for BCL10, in addition to its effects on IKKgamma, the regulatory component of the IKK signalosome, and a requirement for BCL10 in both canonical and noncanonical pathways of NF-kappaB activation. PMID: 19897484 vimplicated in apoptosis, and it has been suggested that mutated forms gain oncogenic activity. The occurrence of genomic BCL10 mutations in gastric MALT-type lymphomas was investigated. PMID: 11830492 Mutations, relatively common in lymphomas, are extremely rare in malignant cartilaginous tumors. PMID: 11836626 REVIEW: Genetic alterations involving BCL10 underlying the pathogenesis of MALT lymphoma PMID: 11960389 There is a lack of BCL10 mRNA mutation in lymphold malignancies. PMID: 12017308 association of mutations with aberrant BCL10 localization in the nucleus in nasal NK/T-cell lymphomas PMID: 14523480 Bcl10 is post-translationally modified by Rip2 and has a role in T-cell signaling PMID: 14638696 Nuclear expression of BCL10 is unlikely to correlate with the API2-MALT1 fusion gene in ocular adnexal MALT lymphoma. PMID: 14674990 Together, these findings suggest that Bcl10 nuclear expression may modulate gene expression and Bcl10 is a potential transcriptional activator apart from its traditional roles that have been found. PMID: 15207693 BinCard inhibits BCL10-mediated activation of NF-kappa B. PMID: 15637807 The ability of Bcl10 expression to prevent B-cell antigen receptor-induced growth arrest and apoptosis of WEHI-231 cells was dependent on NF-kappaB activation. PMID: 15878976 nucleocytoplasmic shuttling of MALT1 and BCL10 complex may indicate that these molecules are involved not only in the nuclear factor kappaB (NF-kappaB) pathway but also in other biologic functions in lymphocytes PMID: 16123224

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

📧 inquiry@betalifesci.com 📞 +1(201) 888-7983

Contact Us Now for Inquiries, Orders, and Questions

Recombinant Human B-Cell Lymphoma/Leukemia 10 (BCL10) Protein (His-SUMO)

Recombinant Human B-Cell Lymphoma/Leukemia 10 (BCL10) Protein (His-SUMO)

Product Overview

Target Details

FAQs